Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar

BACKGROUND: Plasmodium falciparum resistance to artemisinins, the first line treatment for malaria worldwide, has been reported in western Cambodia. Resistance is characterized by significantly delayed clearance of parasites following artemisinin treatment. Artemisinin resistance has not previously...

Full description

Bibliographic Details
Main Authors: Kyaw, M, Nyunt, M, Chit, K, Aye, M, Aye, K, Lindegardh, N, Tarning, J, Imwong, M, Jacob, C, Rasmussen, C, Perin, J, Ringwald, P
Format: Journal article
Language:English
Published: Public Library of Science 2013
_version_ 1797089461239021568
author Kyaw, M
Nyunt, M
Chit, K
Aye, M
Aye, K
Aye, M
Lindegardh, N
Tarning, J
Imwong, M
Jacob, C
Rasmussen, C
Perin, J
Ringwald, P
Nyunt, M
author_facet Kyaw, M
Nyunt, M
Chit, K
Aye, M
Aye, K
Aye, M
Lindegardh, N
Tarning, J
Imwong, M
Jacob, C
Rasmussen, C
Perin, J
Ringwald, P
Nyunt, M
author_sort Kyaw, M
collection OXFORD
description BACKGROUND: Plasmodium falciparum resistance to artemisinins, the first line treatment for malaria worldwide, has been reported in western Cambodia. Resistance is characterized by significantly delayed clearance of parasites following artemisinin treatment. Artemisinin resistance has not previously been reported in Myanmar, which has the highest falciparum malaria burden among Southeast Asian countries. METHODS: A non-randomized, single-arm, open-label clinical trial of artesunate monotherapy (4 mg/kg daily for seven days) was conducted in adults with acute blood-smear positive P. falciparum malaria in Kawthaung, southern Myanmar. Parasite density was measured every 12 hours until two consecutive negative smears were obtained. Participants were followed weekly at the study clinic for three additional weeks. Co-primary endpoints included parasite clearance time (the time required for complete clearance of initial parasitemia), parasite clearance half-life (the time required for parasitemia to decrease by 50% based on the linear portion of the parasite clearance slope), and detectable parasitemia 72 hours after commencement of artesunate treatment. Drug pharmacokinetics were measured to rule out delayed clearance due to suboptimal drug levels. RESULTS: The median (range) parasite clearance half-life and time were 4.8 (2.1-9.7) and 60 (24-96) hours, respectively. The frequency distributions of parasite clearance half-life and time were bimodal, with very slow parasite clearance characteristic of the slowest-clearing Cambodian parasites (half-life longer than 6.2 hours) in approximately 1/3 of infections. Fourteen of 52 participants (26.9%) had a measurable parasitemia 72 hours after initiating artesunate treatment. Parasite clearance was not associated with drug pharmacokinetics. CONCLUSIONS: A subset of P. falciparum infections in southern Myanmar displayed markedly delayed clearance following artemisinin treatment, suggesting either emergence of artemisinin resistance in southern Myanmar or spread to this location from its site of origin in western Cambodia. Resistance containment efforts are underway in Myanmar. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12610000896077.
first_indexed 2024-03-07T03:04:27Z
format Journal article
id oxford-uuid:b2068c6b-4c7d-486d-bf7a-4b42ea8602c9
institution University of Oxford
language English
last_indexed 2024-03-07T03:04:27Z
publishDate 2013
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:b2068c6b-4c7d-486d-bf7a-4b42ea8602c92022-03-27T04:08:41ZReduced susceptibility of Plasmodium falciparum to artesunate in southern MyanmarJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2068c6b-4c7d-486d-bf7a-4b42ea8602c9EnglishSymplectic Elements at OxfordPublic Library of Science2013Kyaw, MNyunt, MChit, KAye, MAye, KAye, MLindegardh, NTarning, JImwong, MJacob, CRasmussen, CPerin, JRingwald, PNyunt, MBACKGROUND: Plasmodium falciparum resistance to artemisinins, the first line treatment for malaria worldwide, has been reported in western Cambodia. Resistance is characterized by significantly delayed clearance of parasites following artemisinin treatment. Artemisinin resistance has not previously been reported in Myanmar, which has the highest falciparum malaria burden among Southeast Asian countries. METHODS: A non-randomized, single-arm, open-label clinical trial of artesunate monotherapy (4 mg/kg daily for seven days) was conducted in adults with acute blood-smear positive P. falciparum malaria in Kawthaung, southern Myanmar. Parasite density was measured every 12 hours until two consecutive negative smears were obtained. Participants were followed weekly at the study clinic for three additional weeks. Co-primary endpoints included parasite clearance time (the time required for complete clearance of initial parasitemia), parasite clearance half-life (the time required for parasitemia to decrease by 50% based on the linear portion of the parasite clearance slope), and detectable parasitemia 72 hours after commencement of artesunate treatment. Drug pharmacokinetics were measured to rule out delayed clearance due to suboptimal drug levels. RESULTS: The median (range) parasite clearance half-life and time were 4.8 (2.1-9.7) and 60 (24-96) hours, respectively. The frequency distributions of parasite clearance half-life and time were bimodal, with very slow parasite clearance characteristic of the slowest-clearing Cambodian parasites (half-life longer than 6.2 hours) in approximately 1/3 of infections. Fourteen of 52 participants (26.9%) had a measurable parasitemia 72 hours after initiating artesunate treatment. Parasite clearance was not associated with drug pharmacokinetics. CONCLUSIONS: A subset of P. falciparum infections in southern Myanmar displayed markedly delayed clearance following artemisinin treatment, suggesting either emergence of artemisinin resistance in southern Myanmar or spread to this location from its site of origin in western Cambodia. Resistance containment efforts are underway in Myanmar. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12610000896077.
spellingShingle Kyaw, M
Nyunt, M
Chit, K
Aye, M
Aye, K
Aye, M
Lindegardh, N
Tarning, J
Imwong, M
Jacob, C
Rasmussen, C
Perin, J
Ringwald, P
Nyunt, M
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title_full Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title_fullStr Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title_full_unstemmed Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title_short Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar
title_sort reduced susceptibility of plasmodium falciparum to artesunate in southern myanmar
work_keys_str_mv AT kyawm reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT nyuntm reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT chitk reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT ayem reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT ayek reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT ayem reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT lindegardhn reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT tarningj reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT imwongm reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT jacobc reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT rasmussenc reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT perinj reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT ringwaldp reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar
AT nyuntm reducedsusceptibilityofplasmodiumfalciparumtoartesunateinsouthernmyanmar